Search

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Western Canada

Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Life forward - Boehringer Ingelheim unveils its evolved company brand

Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners

Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Alberta

Learn about Boehringer Ingelheim Canada's strategic partnerships with leading institutions in Alberta to advance quality healthcare.

Ontario

Boehringer Ingelheim Canada collaborates with premier institutions in Ontario to drive innovative solutions for high-quality healthcare. Click to read more.

Quebec

Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Corporate profile

Purchasing

Purchasing at Boehringer Ingelheim

Boehringer Ingelheim - Value Through Innovation

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study

Application Platform Data privacy statement

(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities

Human Health Partnering

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Brigitte Fuhr

Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.

Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure

New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19

Collaboration key to meeting consumers’ expectations for better animal welfare

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers